Sequoia Financial Advisors LLC Buys 1,883 Sanofi (NASDAQ:SNY) Shares

Sequoia Financial Advisors LLC raised its stake in shares of Sanofi (NASDAQ:SNY – Free Report) by 9.8% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 21,090 shares of the company’s stock after acquiring an additional 1,883 shares during the period. Sequoia Financial Advisors LLC’s holdings in Sanofi were worth $1,023,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of SNY. TCTC Holdings LLC raised its position in Sanofi by 28.0% in the first quarter. TCTC Holdings LLC now owns 960 shares of the company’s stock valued at $47,000 after acquiring an additional 210 shares during the last quarter. Daiwa Securities Group Inc. grew its stake in Sanofi by 3.4% in the fourth quarter. Daiwa Securities Group Inc. now owns 6,541 shares of the company’s stock worth $325,000 after acquiring an additional 216 shares in the last quarter. Wynn Capital LLC boosted its holdings in shares of Sanofi by 4.5% in the first quarter. Wynn Capital LLC now owns 5,266 shares of the company’s stock valued at $256,000 after acquiring an additional 226 shares in the last quarter. Angeles Investment Advisors LLC grew its position in shares of Sanofi by 2.1% in the 4th quarter. Angeles Investment Advisors LLC now owns 12,029 shares of the company’s stock valued at $598,000 after buying an additional 244 shares in the last quarter . Finally, EP Wealth Advisors LLC raised its position in Sanofi by 5.3% in the 4th quarter. EP Wealth Advisors LLC now owns 5,035 shares of the company’s stock worth $250,000 after buying an additional 255 shares. shares in the last quarter. Institutional investors own 10.04% of the company’s shares.

Sanofi stock performance

Shares of SNY stock opened at $53.58 on Wednesday. The firm has a market cap of $135.70 billion, a price-to-earnings ratio of 26.92, a PEG ratio of 1.52 and a beta of 0.59. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65, and a current ratio of 1.00. Sanofi has a 1 year low of $42.63 and a 1 year high of $55.72. The stock’s 50-day moving average is $50.02, and its two-hundred-day moving average is $48.74.

Sanofi (NASDAQ:SNY – Get Your Free Report ) last issued its earnings results on Thursday, July 25th. The company reported $0.93 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.05. The company had revenue of $10.75 billion for the quarter, compared to analyst estimates of $16.86 billion. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. In the same quarter last year, the company posted earnings of $0.95 per share. The company’s revenue for the quarter was up 7.8% compared to the same quarter last year. analysts forecast that Sanofi will post 4.18 earnings per share for the current year.

Changes in Analyst Ratings

Several research analysts have recently issued reports on SNY shares. Argus boosted their target price on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a report on Friday, July 26th. StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Monday. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of “Moderate Buy” and an average price target of $57.50, according to data from MarketBeat.com.

See the latest stock report on Sanofi

About Sanofi

(Free Report)

Sanofi, a healthcare company, is engaged in the research, development, production and commercialization of therapeutic solutions in the United States, Europe and internationally. It operates through Pharmaceuticals, Vaccines and Consumer Healthcare segments. The Company provides specialty care such as DUPIXENT, neurology and immunology, rare diseases, oncology and rare blood disorders; drugs for diabetes and cardiovascular disease; and established prescription products.

Further reading

Want to see what other hedge funds own SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY – Free Report).

Get news and reviews for Sanofi Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Sanofi and related companies with MarketBeat.com’s FREE daily email newsletter.